<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02345434</url>
  </required_header>
  <id_info>
    <org_study_id>JPAL-LETTERS-SII</org_study_id>
    <nct_id>NCT02345434</nct_id>
  </id_info>
  <brief_title>The Effect of Informative Letters on the Prescription and Receipt of Schedule II Controlled Substances</brief_title>
  <official_title>The Effect of Informative Letters on the Prescription and Receipt of Schedule II Controlled Substances</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abdul Latif Jameel Poverty Action Lab</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Medicare and Medicaid Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Services Administration (GSA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Abdul Latif Jameel Poverty Action Lab</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fraud and waste is estimated to cost the American health care system nearly $200 billion each&#xD;
      year, and the public Medicare and Medicaid programs about $60 billion each year. This study&#xD;
      will evaluate a new method for fighting fraud: mailing informative letters to outlier&#xD;
      providers to notify them of their aberrant behavior. These letters are targeted at high&#xD;
      prescribers of schedule II controlled substances in Medicare Part D. The investigators will&#xD;
      look at the effects of these letters on the behavior of providers and their patients. These&#xD;
      effects are of substantial policy interest as they suggest how to best design anti-fraud&#xD;
      policies. They are also of academic interest, shedding light on the behavior of physicians&#xD;
      and their patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30-day Equivalent Prescribing of Schedule II Controlled Substances</measure>
    <time_frame>3 months</time_frame>
    <description>The prescribing of schedule II controlled substances over the 3 months following the initial sending of the letters. Prescribing is defined as the total &quot;days supply&quot; of schedule II controlled substances attributed to the prescriber, expressed in &quot;30-day equivalents&quot; i.e. divided by 30.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-day Equivalent Prescribing of Schedule II Controlled Substances</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day Equivalent Prescribing of Schedule II Controlled Substances</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day Equivalent Prescribing of Schedule II Controlled Substances</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day Equivalent Prescribing of Schedule II Controlled Substances</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1525</enrollment>
  <condition>Economics</condition>
  <condition>Fraud</condition>
  <condition>Delivery of Health Care</condition>
  <condition>Health Expenditures</condition>
  <condition>Centers for Medicare and Medicaid Services (U.S.)</condition>
  <arm_group>
    <arm_group_label>No informative letter</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This is the control arm and it involves no contact with the prescriber</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Informative letter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is the treatment arm; prescribers in this arm receive an informative letter (called a comparative billing report or peer activity report)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Informative letter</intervention_name>
    <description>The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.</description>
    <arm_group_label>Informative letter</arm_group_label>
    <other_name>Comparative billing report</other_name>
    <other_name>Peer activity report</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outlier with respect to the count of schedule II prescription drug events relative to&#xD;
             peer group of prescribers in two of the three years 2011, 2012, and 2013&#xD;
&#xD;
          -  Outlier with respect to the 30-day equivalent prescriptions of schedule II substances&#xD;
             relative to peer group of prescribers in two of the three years 2011, 2012, and 2013&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Deceased&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Finkelstein, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Institute of Technology</affiliation>
  </overall_official>
  <link>
    <url>https://www.socialscienceregistry.org/trials/525</url>
    <description>American Economic Association Randomized Controlled Trials Registry Entry</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 6, 2014</study_first_submitted>
  <study_first_submitted_qc>January 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <results_first_submitted>August 5, 2021</results_first_submitted>
  <results_first_submitted_qc>October 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 8, 2021</results_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There was no recruitment in the traditional sense. High prescribers of Schedule II controlled substances were identified in Medicare administrative data using a Tukey outlier method.</recruitment_details>
      <pre_assignment_details>Seven of the identified outliers had died by the time of the study and were excluded from the intervention and later analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>No Informative Letter</title>
          <description>This is the control arm and it involves no contact with the prescriber</description>
        </group>
        <group group_id="P2">
          <title>Informative Letter</title>
          <description>This is the treatment arm; prescribers in this arm receive an informative letter (called a comparative billing report or peer activity report)&#xD;
Informative letter: The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="763"/>
                <participants group_id="P2" count="762"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="758"/>
                <participants group_id="P2" count="760"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Deceased (excluded from intervention and analysis)</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This baseline measure data was not collected</population>
      <group_list>
        <group group_id="B1">
          <title>No Informative Letter</title>
          <description>This is the control arm and it involves no contact with the prescriber</description>
        </group>
        <group group_id="B2">
          <title>Informative Letter</title>
          <description>This is the treatment arm; prescribers in this arm receive an informative letter (called a comparative billing report or peer activity report)&#xD;
Informative letter: The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Data for Baseline Measures were not collected</population>
          <units>years</units>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Data for Baseline Measures were not collected</population>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>30-day Equivalent Prescribing of Schedule II Controlled Substances</title>
        <description>The prescribing of schedule II controlled substances over the 3 months following the initial sending of the letters. Prescribing is defined as the total &quot;days supply&quot; of schedule II controlled substances attributed to the prescriber, expressed in &quot;30-day equivalents&quot; i.e. divided by 30.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Informative Letter</title>
            <description>This is the control arm and it involves no contact with the prescriber</description>
          </group>
          <group group_id="O2">
            <title>Informative Letter</title>
            <description>This is the treatment arm; prescribers in this arm receive an informative letter (called a comparative billing report or peer activity report)&#xD;
Informative letter: The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.</description>
          </group>
        </group_list>
        <measure>
          <title>30-day Equivalent Prescribing of Schedule II Controlled Substances</title>
          <description>The prescribing of schedule II controlled substances over the 3 months following the initial sending of the letters. Prescribing is defined as the total &quot;days supply&quot; of schedule II controlled substances attributed to the prescriber, expressed in &quot;30-day equivalents&quot; i.e. divided by 30.</description>
          <units>30-day equivalent prescription fills</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="758"/>
                <count group_id="O2" value="760"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="461.1" spread="443.9"/>
                    <measurement group_id="O2" value="450.0" spread="450.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.35</ci_lower_limit>
            <ci_upper_limit>13.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30-day Equivalent Prescribing of Schedule II Controlled Substances</title>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Informative Letter</title>
            <description>This is the control arm and it involves no contact with the prescriber</description>
          </group>
          <group group_id="O2">
            <title>Informative Letter</title>
            <description>This is the treatment arm; prescribers in this arm receive an informative letter (called a comparative billing report or peer activity report)&#xD;
Informative letter: The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.</description>
          </group>
        </group_list>
        <measure>
          <title>30-day Equivalent Prescribing of Schedule II Controlled Substances</title>
          <units>30-day equivalent prescription fills</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="758"/>
                <count group_id="O2" value="760"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.5" spread="148.8"/>
                    <measurement group_id="O2" value="151.1" spread="150.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.68</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30-day Equivalent Prescribing of Schedule II Controlled Substances</title>
        <time_frame>6 months</time_frame>
        <population>Outcome measure not collected for study</population>
        <group_list>
          <group group_id="O1">
            <title>No Informative Letter</title>
            <description>This is the control arm and it involves no contact with the prescriber</description>
          </group>
          <group group_id="O2">
            <title>Informative Letter</title>
            <description>This is the treatment arm; prescribers in this arm receive an informative letter (called a comparative billing report or peer activity report)&#xD;
Informative letter: The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.</description>
          </group>
        </group_list>
        <measure>
          <title>30-day Equivalent Prescribing of Schedule II Controlled Substances</title>
          <population>Outcome measure not collected for study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30-day Equivalent Prescribing of Schedule II Controlled Substances</title>
        <time_frame>9 months</time_frame>
        <population>Outcome measure not collected for study</population>
        <group_list>
          <group group_id="O1">
            <title>No Informative Letter</title>
            <description>This is the control arm and it involves no contact with the prescriber</description>
          </group>
          <group group_id="O2">
            <title>Informative Letter</title>
            <description>This is the treatment arm; prescribers in this arm receive an informative letter (called a comparative billing report or peer activity report)&#xD;
Informative letter: The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.</description>
          </group>
        </group_list>
        <measure>
          <title>30-day Equivalent Prescribing of Schedule II Controlled Substances</title>
          <population>Outcome measure not collected for study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30-day Equivalent Prescribing of Schedule II Controlled Substances</title>
        <time_frame>1 year</time_frame>
        <population>Outcome measure not collected for study</population>
        <group_list>
          <group group_id="O1">
            <title>No Informative Letter</title>
            <description>This is the control arm and it involves no contact with the prescriber</description>
          </group>
          <group group_id="O2">
            <title>Informative Letter</title>
            <description>This is the treatment arm; prescribers in this arm receive an informative letter (called a comparative billing report or peer activity report)&#xD;
Informative letter: The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.</description>
          </group>
        </group_list>
        <measure>
          <title>30-day Equivalent Prescribing of Schedule II Controlled Substances</title>
          <population>Outcome measure not collected for study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>No Informative Letter</title>
          <description>This is the control arm and it involves no contact with the prescriber</description>
        </group>
        <group group_id="E2">
          <title>Informative Letter</title>
          <description>This is the treatment arm; prescribers in this arm receive an informative letter (called a comparative billing report or peer activity report)&#xD;
Informative letter: The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="760"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="758"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="760"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Sacarny</name_or_title>
      <organization>Columbia University</organization>
      <phone>212 305 7084</phone>
      <email>ajs2102@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

